Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker VRDN
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | State Street Corporation | 4.88M | 4.3% | SCHEDULE 13G ↗ |
| Aug 20, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Steven A. Cohen | 5.69M | 5.0% | SCHEDULE 13G ↗ |
| Aug 20, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Point72 Capital Advisors, Inc. | 5.69M | 5.0% | SCHEDULE 13G ↗ |
| Aug 20, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Point72 Asset Management, L.P. | 5.69M | 5.0% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Yue Tang | 0 | 5.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Kynam Capital Management GP, LLC | 0 | 5.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Kynam Capital Management, LP | 0 | 5.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | David Kroin | 3.59M | 3.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Deep Track Biotechnology Master Fund, Ltd. | 3.59M | 3.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Deep Track Capital, LP | 3.59M | 3.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Paradigm BioCapital International Fund Ltd. | 5.90M | 5.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Senai Asefaw, M.D. | 6.72M | 6.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Paradigm BioCapital Advisors GP LLC | 6.72M | 6.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Paradigm BioCapital Advisors LP | 6.72M | 6.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | T. Rowe Price Associates, Inc. | 5.75M | 5.2% | SCHEDULE 13G ↗ |
| Aug 7, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | State Street Corporation | 6.12M | 5.5% | SCHEDULE 13G ↗ |
| Jun 26, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Paradigm BioCapital International Fund Ltd. | 4.94M | 4.5% | SCHEDULE 13G ↗ |
| Jun 26, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Senai Asefaw, M.D. | 5.63M | 5.1% | SCHEDULE 13G ↗ |
| Jun 26, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Paradigm BioCapital Advisors GP LLC | 5.63M | 5.1% | SCHEDULE 13G ↗ |
| Jun 26, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Paradigm BioCapital Advisors LP | 5.63M | 5.1% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Bellevue Asset Management AG | 6.73M | 6.6% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Bellevue Group AG | 6.73M | 6.6% | SCHEDULE 13G ↗ |
| May 13, 2026 | SCHEDULE 13D/A (amended) | VRDN Viridian Therapeutics, Inc. | Fairmount Healthcare Fund II GP LLC | 17.20M | 14.0% | SCHEDULE 13D/A ↗ |
| May 13, 2026 | SCHEDULE 13D/A (amended) | VRDN Viridian Therapeutics, Inc. | Fairmount Funds Management LLC | 17.20M | 14.0% | SCHEDULE 13D/A ↗ |
| May 8, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | David Kroin | 5.42M | 5.3% | SCHEDULE 13G ↗ |
| May 8, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Deep Track Biotechnology Master Fund, Ltd. | 5.42M | 5.3% | SCHEDULE 13G ↗ |
| May 8, 2026 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Deep Track Capital, LP | 5.42M | 5.3% | SCHEDULE 13G ↗ |
| Mar 27, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Yue Tang | 1.47M | 1.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Kynam Capital Management GP, LLC | 1.47M | 1.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Kynam Capital Management, LP | 1.47M | 1.5% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | David Kroin | 2.52M | 2.6% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Deep Track Biotechnology Master Fund, Ltd. | 2.52M | 2.6% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Deep Track Capital, LP | 2.52M | 2.6% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Commodore Capital Master LP | 3.20M | 3.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Commodore Capital LP | 3.20M | 3.9% | SCHEDULE 13G/A ↗ |
| Oct 27, 2025 | SCHEDULE 13D/A (amended) | VRDN Viridian Therapeutics, Inc. | Fairmount Healthcare Fund II GP LLC | 16.03M | 15.1% | SCHEDULE 13D/A ↗ |
| Oct 27, 2025 | SCHEDULE 13D/A (amended) | VRDN Viridian Therapeutics, Inc. | Fairmount Funds Management LLC | 16.03M | 15.1% | SCHEDULE 13D/A ↗ |
| May 15, 2025 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Yue Tang | 0 | 5.8% | SCHEDULE 13G ↗ |
| May 15, 2025 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Kynam Capital Management GP, LLC | 0 | 5.8% | SCHEDULE 13G ↗ |
| May 15, 2025 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Kynam Capital Management, LP | 0 | 5.8% | SCHEDULE 13G ↗ |
| Apr 11, 2025 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Commodore Capital Master LP | 4.30M | 5.3% | SCHEDULE 13G ↗ |
| Apr 11, 2025 | SCHEDULE 13G | VRDN Viridian Therapeutics, Inc. | Commodore Capital LP | 4.30M | 5.3% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Bong Y Koh | 3.58M | 4.5% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Nimish Shah | 3.58M | 4.5% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | VHCP Management EG, LLC | 3.58M | 4.5% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | VHCP Management III, LLC | 3.58M | 4.5% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Venrock Healthcare Capital Partners EG, L.P. | 3.58M | 4.5% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | VHCP Co-Investment Holdings III, LLC | 3.58M | 4.5% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | VRDN Viridian Therapeutics, Inc. | Venrock Healthcare Capital Partners III, L.P. | 3.58M | 4.5% | SCHEDULE 13G/A ↗ |
50 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:46 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances